Use of RGD-enriched gelatine-like proteins for inhibition of cancer metastasis

Abstract

The invention concerns a cell support comprising an RGD-enriched gelatine that has a more even distribution of RGD sequences than occurring in a natural gelatine and with a minimum level of RGD sequences. More precise the percentage of RGD sequences related to the total number of amino acids is at least 0.4 and if the RGD-enriched gelatine comprises 350 amino acids or more, each stretch of 350 amino acids contains at least one RGD motif. Preferably the RGD-enriched gelatines are prepared by recombinant technology, and have a sequence that is derived from a human gelatine or collagen amino acid sequence. The invention also relates to RGD-enriched gelatines that are used for attachment to integrins. In particular The RGD-enriched gelatines of the invention are suitable for coating a cell culture support for growing anchor-dependant cell types. Further, the RGD-enriched gelatines of the invention may find use in medical applications, in particular as a coating on implant or transplant material or as a component of drug delivery systems.

1. A method for inhibition of cancer metastasis in a subject in need thereof, said method comprising administering to a subject an RGD-enriched gelatine, at least 80% of the sequences of said RGD-enriched gelatine consisting of one or more parts of one or more native human collagen sequences each native human collagen sequence part having a length of at least 30 amino acids, said RGD-enriched gelatine having a molecular weight of about 30 kDa to about 200 kDa, and in which RGD-enriched gelatine the number of RGD motifs is an integer and in which the percentage of RGD motifs related to the total number of amino acids is at least 0.4 and if the RGD-enriched gelatine comprises 350 amino acids or more, each stretch of 350 amino acids contains at least one RGD motif wherein said method inhibits cancer metastasis. 
     
     
       2. The method according to  claim 1  wherein the percentage of RGD motifs is selected from the group of percentages consisting of least 0.6, at least 0.8, at least 1.0, at least 1.2 and at least 1.5. 
     
     
       3. The method according to  claim 1  wherein the RGD-enriched gelatine comprises a proportion of RGD motifs of at least 4 per 250 amino acids. 
     
     
       4. The method according to  claim 1  wherein the RGD-enriched gelatine comprises a number of RGD motifs selected from the group consisting of 6, 8, 12, and up to and including 16. 
     
     
       5. The method according to  claim 1  in which the RGD-enriched gelatine comprises less than 5% hydroxyproline residues, or less than 3% hydroxyproline residues. 
     
     
       6. The method according to  claim 1  the RGD-enriched gelatine has a net positive charge at pH 7-7.5. 
     
     
       7. The method of  claim 1  wherein the native human collagen sequences comprises repeats of GXY triplets and approximately one third of the amino acid residues in the native human collagen sequences are glycine residues. 
     
     
       8. The method of  claim 1  wherein the RGD-enriched gelatine is not glycosylated. 
     
     
       9. The method of  claim 8  wherein the RGD-enriched gelatine comprises GXY triplets or regions of GXY triplets separated by one or more amino acids. 
     
     
       10. The method of  claim 1  wherein the native human collagen sequences comprise repeats of GXY triplets and approximately one third of the amino acid residues in the native human collagen sequences are glycine residues, wherein the RGD-enriched gelatine is not glycosylated and wherein the RGD-enriched gelatine comprises GXY triplets or regions of GXY triplets separated by one or more amino acids.